NCT04590235: A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Sponsor: AstraZeneca. Phase: PHASE1. Conditions: Neurofibromatosis 1, Neurofibroma Plexiform